title: Effects of 5-HT1B/1D receptor agonist rizatriptan on cerebral blood flow and blood volume in normal circulation.
abstract: To investigate the vasoconstrictor effect of 5-hydroxytryptamine (5-HT1B/1D) receptor agonists for migraine treatment, changes in cerebral blood flow (CBF) and blood volume induced by rizatriptan were assessed by positron emission tomography (PET). Eleven healthy volunteers underwent PET studies before and after rizatriptan administration. Dynamic PET data were acquired after bolus injection of H2(15)O to analyze CBF and arterial-to-capillary blood volume (V0) images using the three-weighted integral method. After a baseline scan, three further acquisitions were performed at 40 to 50, 60 and 70 to 80 mins after drug administration. Global and regional differences in CBF and V0 between conditions were compared using absolute values in the whole brain and cortical regions, as well as statistical parametric mapping (SPM) analysis. The global and regional values for CBF and V0 decreased significantly after rizatriptan administration compared with the baseline condition. However, both values recovered to baseline within 80 mins after treatment. The maximal reduction in global CBF and V0 was approximately 13% of baseline value. The greatest decrease in CBF was observed approximately 60 mins after drug administration, whereas the maximal reduction in V0 was observed approximately 5 mins earlier. Statistical parametric mapping did not highlight any regional differences between conditions. Thus, in brain circulation, rizatriptan caused significant CBF and V0 decreases, which are consistent with the vasoconstrictor effect of triptans on the large cerebral arteries. The gradual recovery in the late phase from the maximal CBF and V0 decrease suggests that rizatriptan does not affect the cerebral autoregulatory response in small arteries induced by CBF reduction.
authors.affiliation: Biomedical Imaging Research Center, University of Fukui, Fukui, Japan. okazawa@fmsrsa.fukui-med.ac.jp
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Okazawa
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Tsuchida
authors.forename: Marco
authors.initials: M
authors.lastname: Pagani
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mori
authors.forename: Masato
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Fumiko
authors.initials: F
authors.lastname: Tanaka
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Yonekura
mesh_terms: D000328:Adult; D001810:Blood Volume / Q000187:drug effects / Q000502:physiology*; D001921:Brain / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism; D001931:Brain Mapping; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods; D012016:Reference Values; D012680:Sensitivity and Specificity; D058825:Serotonin 5-HT1 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000494:pharmacology; D013997:Time Factors; D014230:Triazoles / Q000008:administration & dosage* / Q000494:pharmacology; D014363:Tryptamines / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D058825:Serotonin 5-HT1 Receptor Agonists; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan